Passumpsic Savings Bank Lowers Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Passumpsic Savings Bank lessened its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,989 shares of the medical equipment provider’s stock after selling 215 shares during the quarter. Intuitive Surgical comprises 2.6% of Passumpsic Savings Bank’s holdings, making the stock its 9th biggest position. Passumpsic Savings Bank’s holdings in Intuitive Surgical were worth $3,925,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical in the second quarter worth about $26,000. Godsey & Gibb Inc. increased its holdings in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the period. LGT Financial Advisors LLC raised its position in Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 54 shares during the last quarter. MidAtlantic Capital Management Inc. acquired a new stake in Intuitive Surgical during the 3rd quarter valued at approximately $33,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in shares of Intuitive Surgical in the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the completion of the transaction, the chief executive officer now owns 24,219 shares of the company’s stock, valued at $12,391,166.97. This trade represents a 42.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Jamie Samath sold 108 shares of Intuitive Surgical stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total transaction of $58,542.48. Following the sale, the chief financial officer now owns 8,757 shares of the company’s stock, valued at approximately $4,746,819.42. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,485 shares of company stock worth $26,128,102. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Down 0.1 %

NASDAQ ISRG opened at $538.09 on Wednesday. Intuitive Surgical, Inc. has a 52 week low of $309.80 and a 52 week high of $556.23. The business’s fifty day simple moving average is $517.16 and its 200-day simple moving average is $475.65. The firm has a market cap of $191.66 billion, a PE ratio of 86.51, a P/E/G ratio of 5.41 and a beta of 1.38.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Research analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on ISRG. Royal Bank of Canada raised their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a report on Friday, October 18th. Robert W. Baird boosted their price objective on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Raymond James raised their target price on Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Citigroup raised their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $541.33.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.